Tuesday, March 24, 2015 7:58:25 PM
The article reads as if TTNP recently filled their clinical patient quota....
They also give an incorrect completion date,as the clinical trial was filled as of November 20, 2014.
This would make approximately May 20, 2015 the date said clinical trial should end; not the end of July, as they report.
The article in question is LOCATED BY CLICKING HERE.
Misleading and Inaccurate Information Highlighted In Red Below:
Titan Pharmaceuticals, Inc. (OTCBB:TTNP) Completes Enrollment For Phase 3 Study Of Probuphine
By Miles Sandford on March 24, 2015
Titan Pharmaceuticals, Inc. (OTCBB:TTNP) said that the company is making good progress with its Phase 3 Study Of Probuphine. The company completed enrollment of patients for its pivotal Phase 3 trial of Probuphine. The drug candidate will treat the patients who suffer from opioid dependence. The medication is categorized as an investigational subdermal plant. The trial is anticipated to end by July 2015. Once the trial is over, Titan will resubmit NDA to the FDA later in this year.
The process
Braeburn Pharmaceuticals is assigned the responsibility of the Phase 3 trial. Titan will serve as the key sponsor of Probuphine trial. As of now, the company has selected 178 patients for the key study. The enrollments have been randomized in twenty-one different centers. The enrollment process was easy as the screening failure was less in the process. Also, patients showed high interest towards the study. It hardly took four months to complete the enrollment process. Braeburn is expanding its drug portfolio for opioid dependence. The new association will result in additional $50 million of future royalties for the company.
The developments
Kate Glassman Beebe of Titan Pharmaceuticals said that management is encouraged with the progress of Phase 3 trial of Probuphine. The company will assist Braeburn Pharmaceuticals at every step to finish the trial effectively. The plan is expected to yield a controlled review of Probuphine. The study can be termed as a double-blind form and double-dummy design form of research.
Classification
The assessment will be carried out in two categories. The enrollment process covered those people who are stated as clinically stable. These patients are taking maintenance treatment of sublingual formulation which contains buprenorphine. Titan Pharmaceuticals, Inc. (OTCBB:TTNP) said that the duration of trial will be nearly six months. Probuphine has potential to deliver stable amount of buprenorphine during this period. It is an implantable alternative for opioid dependence.
I've never claimed to have all the answers but feel i'm beginning to corner the market in questions worthy of solutions.
Recent TTNP News
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 08/21/2024 12:32:38 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 08/19/2024 08:23:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/19/2024 08:22:56 PM
- Titan Pharmaceuticals Enters Into Merger Agreement With KE Sdn. Bhd. • GlobeNewswire Inc. • 08/19/2024 08:11:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/15/2024 01:29:55 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/15/2024 01:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 09:33:11 PM
- Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria • GlobeNewswire Inc. • 01/25/2024 09:29:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 09:59:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 10:13:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:30:20 PM
- Titan Pharmaceuticals Announces Reverse Stock Split and Ratio • GlobeNewswire Inc. • 12/28/2023 09:15:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2023 09:47:46 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/17/2023 09:03:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/15/2023 09:05:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:33:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:31:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:29:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:25:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:23:37 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 10/24/2023 09:26:34 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/23/2023 07:07:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2023 09:08:35 PM
- Titan Pharmaceuticals Announces Appointment of Dato' Seow Gim Shen and Brynner Chaim to the Company's Board of Directors • GlobeNewswire Inc. • 10/16/2023 08:37:23 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 10/04/2023 09:30:18 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM